

## FORM 7 MONTHLY PROGRESS REPORT

**Name of Listed Issuer:** AREV Nutrition Sciences Inc. ("AREV" or the "Issuer")

**Trading Symbol:** AREV

**Number of Outstanding Listed Securities:** 14,213,209

**Date:** January 11, 2018

Report on Business:

- 1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.**

The Issuer, AREV Nutrition Sciences Inc. ("AREV"), produces and delivers functional ingredients from its world-class extraction system. AREV is revolutionizing the current delivery method of coconut oil, whey protein and nutrients through emulsification. These premium ingredients and products are targeted for the natural health, medical, functional food, nutraceutical, sport nutrition and bioceutical markets. AREV is also working with Pharmacy and Dispensary operators with an innovative emulsified base formula to disperse Cannabis oil extracts from specific selected genetic Cannabis strains that address 5 areas of health including Anxiety, Pain management, Insomnia, Central Nervous System Disorders & Sexuality.

During the month of December, 2017 AREV Nutrition Sciences Inc. is pleased to announce that Adrian Wade through URSA Technologies has joined the team as project manager of AREV effective immediately. Further, AREV has formed an advisory committee made up of Adrian Wade, Ph.D, Christina Juneau, Ph.D, and Dr. Shabtai Bittman.

Adrian P. Wade Ph.D., C.Chem., MRSC, MCIC, MCSC - Dr. Wade is an analytical chemist and computer scientist who is currently the Chief Science Officer of Alternative Extracts Inc. He has published over 50 scientific papers, including work in automated chemical analysis, flow injection analysis, automated extraction methods and chromatography. He is Co-owner and Manager of Ursa Technologies Ltd. (founded 1994), which provides chemistry consulting services and undertakes research and development in process analytical chemistry and methods development. He taught analytical chemistry at University of British Columbia (1987-94) and was a Visiting Research Associate at Michigan State University (1985-87). He obtained his Ph.D. from University of Wales in 1985, and his B.Sc. from University of Southampton in 1981. He serves as a Director and Officer for Alternative Extracts Inc. where he is responsible for science and methods development. Since 2005 he has served as a Director of Goknet Mining Company Ltd.,

where he provides scientific and technical expertise relating to their projects in Ghana. He recently joined the Board of UC Resources Ltd as an independent Director. He is a resident of British Columbia.

Dr Christina Juneau is the Scientific Director at TransBIOTech and she holds a B.Sc in Biochemistry and a Ph.D. in Food Science, both from Université Laval. Dr Juneau has more than 25 years of experience in the pharmaceutical and biotechnology industry, more specifically in the conception and development of therapeutic products, in the manufacturing processes, in the regulatory aspects related to oral and topical drugs and natural health products development, as well as in the intellectual properties and market introduction aspects of various compounds. She has an extensive experience in the design and management of applied R&D projects and she is the co-author on more than 20 patents and peer reviewed scientific articles.

Dr. Shabtai Bittman - Dr. Bittman is a principal research scientist with Agriculture and Agri-Food Canada in Agassiz, BC, and previously in SK and NS, specializing in crop production. He studied and taught Plant Ecology at McGill University and Crop Physiology (water stress) at the University of Saskatchewan. His research has been focused on minimizing environmental impacts of food production with advanced cropping and nutrient management practices. Recent efforts include the reduction of emissions of nitrogenous gases and particulates to the atmosphere and the improvement of water quality through strategic manure use. Dr. Bittman developed the Canadian Agri-Environmental Health Indicator for Atmospheric Ammonia and co-chairs the UNECE Expert Panel on Mitigating Agricultural Nitrogen. He has won national and international awards for his research accomplishments. He founded and operates the website [farmwest.com](http://farmwest.com).

For a more complete list of Dr. Shabtai Bittman's significant achievements, it can be found at <http://www.agr.gc.ca/eng/science-and-innovation/research-centres/british-columbia/agassiz-research-and-development-centre/scientific-staff-and-expertise/bittman-shabtai-phd/?id=1181931198581>

During the month of December, 2017 AREV Nutrition Sciences Inc. is pleased to announce that a second extraction system ("extractor") has been ordered from Alternative Extracts Inc. (AEI) for delivery to Jamaica.

The extractor arrived in Quebec today for modifications that will increase its production capacity from 20 litres to 80 litres. Once the modifications are completed, the extractor will be shipped to a preferred partner in Jamaica that is still to be determined. AREV is in discussions with two potential companies and will select the company that aligns with the company's vision.

The AEI extractor, removes oils without the use of destructive high-temperature, steam distillation or aggressive solvents and is the only known extractor to combine alcohol and

CO<sub>2</sub> supercritical and critical technologies in one efficient process. AREV's first system from AEI is the only known system to use ethanol, supercritical and subcritical CO<sub>2</sub> technologies combined in a single system. It also allows more than one extract to be drawn from a single biomass, and for collection of extract fractions. The second system has been designed specifically to meet the needs of AREV's partners in Jamaica.

**2. Provide a general overview and discussion of the activities of management.**

During the month of December, 2017, management was mainly engaged in, forging ahead with cementing key relationships with industry players as well as interviewing key sales team members to join the AREV team. In addition, management is working to further discussions with Canadian and International distributors with final agreements expected to conclude shortly.

**3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.**

None.

**4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.**

None.

**5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.**

None.

**6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.**

None.

**7. Describe any acquisitions by the Issuer dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or**

disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None.

**8. Describe the acquisition of new customers or loss of customers.**

None.

**9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.**

None.

**10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.**

None.

**11. Report on any labour disputes and resolutions of those disputes if applicable.**

None.

**12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.**

None.

**13. Provide details of any indebtedness incurred or repaid by the Issuer with the terms of such indebtedness together.**

None.

**14. Provide details of any securities issued and options or warrants granted.**

None.

**(1) State aggregate proceeds and intended allocation of proceeds.**

None.

**15. Provide details of any loans to or by Related Persons.**

None.

**16. Provide details of any changes in directors, officers or committee members.**

None.

**17. Discuss any trend which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.**

The trends and risks which are likely to impact the Issuer are discussed in the Issuer's financial statements (the "YE Financial Statements") and corresponding management's discussion and analysis (the "YE MD&A") for the year-ended December 31, 2016. The Q4 Financial Statements and YE MD&A are both available under the Issuer's profile on SEDAR at [www.sedar.com](http://www.sedar.com).

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: January 11, 2018

Stephane Maher

Name of Director or Senior Officer



Signature

Chief Executive Officer and Director Official Capacity

Issuer Details	For Month End	Date of Report
Name of Issuer AREV Nutrition Sciences Inc.	December, 2017	11/01/2018
Issuer Address		
440 - 890 West Pender Street		
City/Province/Postal Code	Issuer Fax No. N/A	Issuer Telephone No. (608) 868 - 5013
Vancouver, BC V6C 1J9		
Contact Name Stephane Maher	Contact Position CEO, Interim CFO and Director	Contact Telephone No. (604) 868 - 5013
Contact Email Address	Web Site Address	
valens@shaw.ca	http://arevnutrition.com/	